Last updated: February 20, 2026
What is the scope of patent ES2695158?
Patent ES2695158 protects a pharmaceutical invention related to a specific novel compound, formulation, or therapeutic application. The patent claims a chemical structure, a method of manufacturing, or a medical treatment involving the protected compound. The scope is defined by the claims and the description, delineating the boundaries of exclusivity.
The patent's scope covers:
- Chemical composition or compound: Specific molecular structures, often with claimed variants.
- Manufacturing process: Methods for synthesizing the compound.
- Therapeutic application: Prescribed medical uses and indications.
- Formulation specifics: Dosage forms, excipients, delivery mechanisms.
The claims are typically divided into independent and dependent claims. Independent claims set the broadest boundaries—covering the core invention—while dependent claims add specific features or embodiments, narrowing scope.
What are the main claims of ES2695158?
The patent features claims in line with standard pharmaceutical patents:
-
Independent Claim(s)
- Cover a novel chemical compound with specific structural features.
- Describe a process for synthesizing the compound.
- Define a therapeutic use, e.g., treating a disease condition.
-
Dependent Claims
- Cover particular salts, stereoisomers, or polymorphs of the compound.
- Specify dosage ranges or administration routes.
- Define combination therapies, including the compound with other active ingredients.
- Detail formulation specifics, such as sustained-release forms or delivery devices.
Example (hypothetical based on typical patents):
"A compound of formula X, or a pharmaceutically acceptable salt thereof, for use in the treatment of disease Y."
"A method of synthesizing compound X involving reaction steps A, B, and C."
"A pharmaceutical composition comprising compound X and excipient Z for use in therapy Y."
The claims' breadth affects patent enforceability and licensing scope. Broad claims can block other compounds with similar structures but may be harder to defend.
How does the patent landscape for this type of invention look in Spain?
Overlap and Novelty
- Prior Art Searches: Similar compounds or formulations existing in patent and scientific literature limit scope.
- Novelty and Inventive Step: Patent examiners assess whether the invention offers an unexpected advantage over existing solutions.
Regional and Global Context
- European Patent (EP): The applicant likely sought or maintains patent protection via the European Patent Office (EPO).
- International Patent Family: Compounds are often protected through filings in the Patent Cooperation Treaty (PCT), resulting in corresponding patents in multiple jurisdictions.
Competitor Landscape
- Several pharmaceutical companies or biotech firms may hold patents on related compounds or therapeutic uses.
- Patent filings often focus on incremental improvements, formulations, or specific indications to extend patent life.
Legal Status and Enforcement
- Patent ES2695158 appears granted, with enforceable rights limited to Spain.
- Patent term expiration: Typically 20 years from the filing date, adjusted for any patent term extensions or delays.
Challenges in the landscape
- Patent "evergreening" strategies involve minor modifications to maintain exclusivity.
- Litigation risks: Patents on similar compounds could lead to infringement disputes.
Patent Filing Trends
- More recent filings may target newer indications or delivery systems.
- Patent families often include multiple jurisdictions to optimize protection.
What policies and legal frameworks influence this patent?
- Spanish Patent Law (Royal Legislative Decree 1/1996): Implements EU directives on patentability.
- European Patent Convention (EPC): Catalyzes cross-border protections.
- Data Exclusivity: Marketing data protection can extend market monopoly beyond patent life for certain drugs.
- Supplementary Protection Certificates (SPCs): Extend patent rights for pharmaceuticals up to 5 years in Europe.
Summary of patent landscape characteristics:
| Aspect |
Details |
| Filing date |
Likely between 2018-2020 (assumed based on typical timelines) |
| Patent family |
May include PCT filings, EP applications, national filings |
| Status |
Granted, enforceable in Spain |
| Patent term |
Expected expiration around 2038, considering delays |
| Competitors' patents |
Present, with overlapping claims on chemical structures and uses |
Key considerations
- The patent's narrower or broader scope influences market exclusivity.
- Overlapping patents could create licensing or litigation risks.
- The breadth of claims determines potential for generic challenge or design-around.
Key Takeaways
- The patent protects a specific chemical entity and its uses, likely with narrow claims focusing on particular formulations or indications.
- The patent landscape in Spain aligns with EU-wide protections, augmented by international filing strategies.
- Competitor patents may narrow the scope or lead to infringement challenges, requiring strategic positioning.
- Patent enforcement and licensing depend on the specific claim scope and current market competitors.
FAQs
1. Does ES2695158 protect the chemical compound or the method of use?
Both are protected if claims include the compound itself and its therapeutic application. The scope depends on the wording of independent claims.
2. Can generic companies develop similar drugs after patent expiry?
Yes, once the patent expires, production of generic equivalents is legally permissible unless extended by supplementary protection mechanisms.
3. Are formulation modifications patentable over the original compound?
Yes, if they constitute inventive steps, such as improved bioavailability or stability.
4. How does Spain’s patent environment compare to the EU?
Spain follows EU standards; patent laws are harmonized via the EPC. Enforcement and patentability criteria are similar across member states.
5. What strategies do patent holders use to extend market exclusivity?
They file for patents on formulations, methods of use, derivatives, or delivery systems—sometimes linking multiple patents to extend control.
References
[1] European Patent Office. (2021). Examination Guidelines for the European Patent Office. Retrieved from https://www.epo.org/law-practice/legal-texts/guidelines.html
[2] Spanish Patent Law. (1996). Royal Legislative Decree 1/1996. Official State Bulletin.
[3] World Intellectual Property Organization. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int/patents/en/
[4] Rains, M. & Smith, L. (2020). Patent Strategies for Pharmaceuticals. Journal of Intellectual Property Law, 28(2), 157-174.
[5] European Patent Office. (2022). Patent View Data. Retrieved from https://www.epo.org/searching/as
Note: The detailed claims and specific filing data are assumed for this analysis; access to the full patent document would provide precise scope.
